Recurrent Optic Neuritis and Perineuritis Followed by an Unexpected Discovery

From the National Multiple Sclerosis Society Case Conference Proceedings

Daniela A. Pimentel Maldonado, MD, MSCR, Robert Lisak, MD, Steven Galetta, MD, Laura Balcer, MD, MSCE, Thomas Varkey, Andrew Goodman, MD, Jennifer Graves, MD, PhD, Michael Racke, MD, Scott S. Zamvil, MD, PhD, Scott Newsome, DO,* Elliot M. Frohman, MD, PhD,* and Teresa C. Frohman, MPAS, PA-C*

Neurol Neuroimmunol Neuroinflamm 2023;10:e200051. doi:10.1212/NXI.00000000000200051

Abstract

We describe a woman with a history of relapsing acute optic neuritis and perineuritis. Testing failed to confirm a specific diagnosis; hence, she was diagnosed with seronegative neuromyelitis optica spectrum disorder and treated with the immunotherapy rituximab, later in conjunction with mycophenolate mofetil. She achieved a durable remission for 9 years until she presented with paresthesia affecting her left fifth digit, right proximal thigh, and left foot, while also reporting a 25-pound weight loss over the prior 3 months. New imaging demonstrated a longitudinally extensive and enhancing optic nerve, in conjunction with multifocal enhancing lesions within the spinal cord, in a skip-like distribution. The differential diagnosis is discussed.

*These authors contributed equally to this work as co–senior authors.
Case Presentation

In September 2020, a 67-year-old woman presented with a 2-day history of left eye burning and difficulty reading fine print (Figure 1). Her clinical history dates to January 2009 when she presented with a 10-day history of progressive, painful central vision loss in her right eye. The ophthalmologic examination at that time was remarkable for a visual acuity (VA) of 20/50 OD and 20/25 OS. There was decreased color vision in the right eye, a right afferent pupillary defect, and right optic disc swelling with areas of hemorrhage. The aquaporin-4 antibody (anti-AQP4; assessed by cell-based assay [CBA]) was negative, and she was diagnosed with right anterior optic neuritis (ON).

MRI of the brain and orbits (with fat suppression) with and without contrast (Figure 2) showed greater than 50% T1 enhancement of the right optic nerve extending to the level of the optic chiasm and with prechiasmatic involvement of the contralateral optic nerve, most consistent with an inflammatory process localized to the orbital segments of the optic nerves and sheath (i.e., perineuritis). MRI of the cervical and thoracic spinal cord was unremarkable. CT of the chest was normal.

Glossary

ACE = angiotensin-converting enzyme; anti-AQP4 = aquaporin-4 antibody; BNS = Bing-Neel syndrome; BTK = Bruton tyrosine kinase; CBA = cell-based assay; CLL = chronic lymphocytic lymphoma; ED = emergency department; MMF = mycophenolate mofetil; MOG = myelin oligodendrocyte glycoprotein; MOGAD = MOG antibody disease; NMOSD = neuromyelitis optica spectrum disorder; ON = optic neuritis; RBC = red blood cell; VA = visual acuity; WBC = white blood cell; WM = Waldenstrom macroglobulinemia.

Figure 1 Chronologic Heat Map

In this figure, we detail the condition of the patient over time. The longitudinal axis (left to right) depicts the condition of disease, where the smaller amplitude and lighter color indicates greater stability of disease. Alternately, the expanded amplitude of the colored heat map (above and below the horizontal linear axis over time) designates increased disease activity (whether on a clinical or paraclinical basis) or complications of the treatment of disease. Other fields of information are added either above or below the heat map and include information about treatments, diagnoses, commentaries adding contextual perspectives, and results from specific test assessments from each most relevant period of clinical decision-making. Each field is consistently color-coded throughout as defined in the figure legend.
CSF examination showed 1–2 white blood cells (WBCs) and 738 and 8 red blood cells (RBCs) in tubes 1 and 4, respectively. Glucose was 111 mg/dL (serum glucose 150–160 mg/dL), and protein was 32 mg/dL. There were 4 oligoclonal bands unique to the CSF. Flow cytometry was unrevealing.

Additional assessments included thyroid-stimulating hormone (which was low at 0.18 IU/mL [ref: 0.50–4.50 IU/mL]) with a normal free T4. Other negative or unremarkable tests included serum angiotensin-converting enzyme (ACE), anti–double stranded DNA antibodies, anti-neutrophilic cytoplasmic antibodies, anti-nuclear antibodies, anti-SSA (anti–Sjögren syndrome–related antigen A autoantibodies), and anti-SSB (anti–Sjögren syndrome–related antigen B autoantibodies), complement levels of C3 and C4, cardiolipin antibody panel, erythrocyte sedimentation rate, C-reactive protein, vitamin B12, RBC folate, vitamin B6, vitamin B1, methylmalonic acid, homocysteine, and beta-2-glycoprotein antibodies.

Subsequently, her right eye vision worsened to hand motion only and was associated with disc edema and multifocal hemorrhages, prompting treatment with IV methylprednisolone for 3 days, followed by an 11-day oral prednisone taper. Vision on the right remained at hand motion only.

In August 2009, she again was diagnosed with right anterior ON. A brain MRI revealed increased thickening and diffuse abnormal enhancement of the right optic nerve. Repeated and now borderline positivity for anti-SSA and an elevated serum angiotensin-converting enzyme (ACE) (81 U/L; normal 9–738 and 8 red blood cells (RBCs) in tubes 1 and 4, respectively). Glucose was 111 mg/dL (serum glucose 150–160 mg/dL), and protein was 32 mg/dL. There were 4 oligoclonal bands unique to the CSF. Flow cytometry was unrevealing.

In November 2009, the patient presented to the emergency department (ED) with painful, new left eye vision loss. VA was 20/20-2 in the left eye, in conjunction with decreased VA in the right eye to hand motion only. She was diagnosed with left-sided acute ON. Brain MRI showed diffuse enhancement of the right optic nerve with slight thickening and enhancement of the prechiasmal left optic nerve. She received both IV and oral corticosteroids, which led to complete resolution of her left-sided ON. The steroid-sparing agent mycophenolate mofetil (MMF) was initiated in March of 2010 at 1 g oral twice daily, based on a working diagnosis of seronegative neuromyelitis optica spectrum disorder (NMOSD).

Approximately 1 year later, the patient was noted to have slightly decreased left eye VA (20/30) and decreased color vision. She again received IV and oral corticosteroids, and the dose of MMF was increased to 1.5 g twice daily with subsequent recovery to her baseline VA. Despite dose escalation of MMF, 4 months later, the patient experienced recurrent left ON (Figure 2). She was then started on rituximab. She experienced yet another episode of right-sided ON in March of 2012 (Figure 1), at which time her CD19 level was at 1%, a level that can be associated with rituximab failure (typically when the CD19% is between 1% and 2.5%). Monthly monitoring of CD19 counts was initiated so that rituximab redosing was instituted when CD19 levels exceeded 0%.

The patient remained stable on rituximab for approximately 9 years, until September 2020, when she noted worsening of her vision in the left eye. She then developed paresthesia in her left 5th digit, right upper thigh, and left foot. Referred to the ED, she was found to have a minimally reactive left pupil without pain with extraocular eye movements. Serum anti-AQP4 and myelin oligodendrocyte glycoprotein (MOG) antibodies, assessed by CBA, were negative. CSF analysis and infectious workup were unrevealing. The patient reported a 25-pound weight loss over the prior 3 months, and her peripheral WBC count had been consistently elevated >13,000 WBCs/μL.

Axial T1 MRI sequences with gadolinium revealed evidence of a longitudinally extensive segment of left optic nerve enhancement (Figure 3). Furthermore, T1 postcontrast MRIs of the spinal cord demonstrated several areas of contrast...
enhancement, in conjunction with the incidental identification of extensively disseminated mediastinal and retroperitoneal lymphadenopathy.

**Differential Diagnosis**

Our patient initially presented with several episodes of longitudinally extensive anterior ON, some with chiasmatic and perineural involvement signifying perineuritis, in conjunction with evidence of optic disc hemorrhages, all red flags for typical demyelinating ON. The triggers for these recurrent attacks were varied and most notably included the failure of MMF treatment in conjunction with CD19 hyper-repopulation while receiving treatment with rituximab (Figure 1). The later development of leptomeningeal enhancement seen on MRI led us to consider other disorders and widen the differential diagnosis.

**Inflammatory and Infectious Considerations**

ON in multiple sclerosis is typically unilateral with mild to moderate vision loss with diffuse or central visual field loss (Table). Ophthalmoscopy is typically unremarkable acutely (given the retrobulbar localization of the initial lesion in most), and MRI might demonstrate unilateral, retrobulbar, and/or canalicular short anterior segment lesions with optic nerve enhancement acutely in most (Table). NMO and MOG antibody disease (MOGAD) ON commonly results in severe vision loss and is frequently bilateral, with distinguishing features on MRI and on fundus examination (Table). Both NMOSD and MOGAD may present with longitudinally extensive optic nerve and spinal cord (≥3 vertebral segments) lesions on MRI, with more frequent involvement of the lower cord and conus associated with MOGAD. Alternately, NMOSD is more likely to affect the intracranial portion of the optic nerve, optic tracts, and optic chiasm and can also feature periependymal, fornix, and hypothalamic lesions. MOGAD ON is more likely to be associated with optic disc edema, with or without hemorrhage, often in conjunction with inflammation of the optic nerve sheath, which can extend into the intraorbital portion of the nerve. Indeed, the AQP4 and MOG antibodies were negative in our patient. However, given that NMOSD can be associated with either B- or T-cell lymphomas, we hypothesize that the reduced efficacy derived from B-cell therapy in AQP4 antibody–negative patients could signify that the underlying pathobiology can be contingent on cellular rather than humoral immune mechanisms.

Neurosarcoidosis can present with either a relapsing subacute optic neuropathy that resembles a demyelinating ON or with a slowly progressive optic neuropathy. About a third of cases show concurrent intraocular inflammation (pan uveitis), and MRI shows optic nerve involvement in 75% of cases. Response to treatment with corticosteroids is adequate, although relapses are common. Sarcoïdosis and other granulomatous disorders (such as granulomatosis with polyangiitis), infectious etiologies (such as tuberculosis, herpetic infections, Bartonella, and Lyme disease), hyperthyroidism, collagen vascular disorders among other entities can also result in optic perineuritis in addition to distinctive clinical manifestations compared with ON in isolation such as exophthalmos, ophthalmoplegia, ptosis, in the correct clinical context (similar to that seen with MOGAD) as well as with meningeal enhancement and thickening.

The enhancement and thickening can be associated with highly characteristic imaging signatures such as ‘tram tracks’ (on axial cuts) and the ‘donut sign’ (on coronal cuts) (Table).
| Table | Distinguishing Features of Optic Neuritis, Perineuritis, and Neoplastic Targeting of the Anterior Visual System |
|-------|-----------------------------------------------------------------------------------------------------|

### MS

**Clinical features**
- Typically, unilateral with reduced visual acuity and color vision; commonly with pain.²
- Sex distribution (F:M): 2–3:1.
- Clinical outcome: patients experience good recovery of function with treatment.

**Examination**
- Ophthalmoscopy unremarkable in 80–90% due to retrobulbar distribution of lesion. Color desaturation is common; however, severe vision loss occurs in about 1/3 of patients. Relative afferent pupillary defect nearly uniform. Any visual field abnormality.

**Imaging**
- MRI typically unilateral, retrobulbar, and canalicular short anterior segment lesions; enhancement in most.

**Neurophysiology**
- P100 latency prolongation common; absent VEP response.

**OCT**
- Peripapillary pRNFL and GCL/IPL thinning is common.

### NMOSD

**Clinical features**
- Severe visual acuity loss, to hand motions only, and even to no light perception; unilateral or bilateral; with pain.
- Sex distribution (F:M): 9:1.
- Clinical outcome: reduced recovery across all domains of visual system function, particularly when compared with MS AON. Treatment: corticosteroids and PLEX

**Examination**
- Severe vision loss with visual acuity worse than 20/200 in 80% or more. Severe color desaturation and visual field abnormality. Fundus findings may be normal; disc edema not unusual.

**Imaging**
- Lesion tends to be longitudinally extensive with confluence analogous to the spinal cord in NMOSD

**Neurophysiology**
- Prolongation in P100 latency is common; amplitude attenuation is uncommon; absent VEP response is common.

**OCT**
- pRNFL and GCL/IPL thinning often severe.

### MOGAD

**Clinical features**
- Severe visual acuity loss, bilateral in ~40%; pain common.
- Sex distribution (F:M): 1:1
- Typically, good neurologic recovery with MOGAD.

**Examination**
- Severe vision loss in 80% or more of patients. Color desaturation and visual field loss severe. Disc edema and optic disc hemorrhages occur.

**Imaging**
- Skip or longitudinally extensive lesions. Perineuritis and/or orbital fat enhancement is common; strongly differentiates this form of AON from other etiologies.

**Neurophysiology**
- Prolongation in P100 latency is common; amplitude attenuation is common; however, an absent VEP response is exceptional.

**OCT**
- pRNFL and GCL/IPL thinning is commonly severe.

### GFAP ON

**Clinical features**
- Rare vision loss; typically bilateral; pain rare. May mimic papilledema, but CSF opening pressure is normal. Sex distribution (F:M): 1:1. mono/multiphasic.

**Examination**
- Vision loss is uncommon. Color vision is generally normal. Visual fields are normal in ~50% of patients; enlarged blind spots are common. Disc edema is common.

**Imaging**
- Optic nerve enhancement is rare. A highly conspicuous pattern of brain enhancement following a radial geometry (radial glia pattern) can be a characteristic.

**Neurophysiology**
- Prolongation in P100 latency is common; amplitude attenuation is common; absent VEP response is uncommon.

**OCT**
- pRNFL and GCL/IPL thinning is commonly severe.

### CRMP5

**Clinical features**
- Slowly progressive painless visual loss.
- Sex distribution (F:M): 1:1. Visual acuities from 20/20 to count fingers. Visual loss usually progressive. Outcome dependent on treating underlying cancer.

**Examination**
- Disc swelling often with retinitis and uveitis.

**Imaging**
- High signal of the optic nerve, often without enhancement.

**Neurophysiology**
- Prolongation in P100 latency.

**OCT**
- Hyperreflectivity; granular pattern outer macular atrophy.

### Perineuritis

**Clinical features**
- Most commonly unilateral. Protracted and progressive painful course of vision loss. Idiopathic, or associated with sarcoid, IgG4-related disease, inflammatory bowel disease, hyperthyroidism, Bechet, collagen vascular disorders, giant cell arteritis, infections such as syphilis, tuberculosis, herpes family infections, as a coincident finding with neuroretinitis (e.g., cat scratch disease from Bartonella Henselae and Lyme disease), and with leukemia, as well as with primary or metastatic malignancy.
### Table Distinguishing Features of Optic Neuritis, Perineuritis, and Neoplastic Targeting of the Anterior Visual System (continued)

| Neoplastic Targeting | Malignant infiltration | Leptomeningeal carcinomatosis | Leptomeningeal lymphoma | Paraneoplastic disorders of the anterior visual system |
|----------------------|------------------------|-----------------------------|------------------------|----------------------------------------------------|
| **Clinical features** | Painless visual loss, ranging from floaters to simple blurring of the vision to severe vision loss or total light blindness. Masquerades as optic neuritis, perineuritis, or uveitis, responds to steroids, confounding the diagnosis. |
| **Examination** | Can be normal, or with disc swelling, relative afferent pupillary defects, and peripapillary hemorrhages (cotton wool spots). |
| **Imaging** | MRI studies typically demonstrate optic nerve contrast enhancement with or without optic nerve thickening. In a study of 22 different cases, significant enlargement of the lesions was observed in nearly every patient with the intracanalicular ON and on the optic chias.29 |
| **Neurophysiology** | VEPs can be delayed and exhibit flattening responses. |
| **OCT** | OCT image hazing of the ocular media because of vitreous involvement. OCT findings demonstrate nodular hyperreflective lesions indicative of lymphomatous deposits in the intraretinal and subretinal pigment epithelium. Cystoid macular edema typically absent.34 |

**Abbreviations:** AON = acute optic neuritis; CRMP5 = collapsin response-mediator protein-5; GCL/IPL = ganglion cell layer/inner plexiform layer; GFAP = glial fibrillary acidic protein; MOGAD = myelin oligodendrocyte glycoprotein antibody disease; MS = multiple sclerosis. NMOSD = neuromyelitis optica spectrum disorders; OCT = optical coherence tomography; ON = optic neuritis; pRNFL = peripapillary retinal nerve fiber layer; PLEX = plasma exchange; VEP = visual evoked potential.

Autoimmune etiologies of ON (e.g., Sjögren syndrome and systemic lupus erythematosus) can feature retrobulbar optic nerve enhancement.3 IgG4-related ophthalmic disease manifestations include ON with inflammation of the optic nerve sheath, compressive optic neuropathy, myositis, and infraorbital redundant fat inflammation.12 Individuals with IgG4-related disease with neurologic involvement typically have systemic disease (e.g., recurrent pancreatitis). Seronegative autoimmune optic neuropathy, such as chronic relapsing inflammatory optic neuropathy or relapsing isolated ON, may present with severe bilateral (simultaneous or sequential) ON with MRI features including retrobulbar optic nerve enhancement with occasional nerve swelling (Table).4,12

**Malignant Infiltration, Leptomeningeal Disease, and Paraneoplastic Disorders**

Our patient was stable on treatment with rituximab for several years. If one considers seronegative NMOSD to be the cause of her recurrent bouts of ON, it is safe to assume that rituximab helped keep her neuroinflammatory disorder under control for several years before the most recent symptoms associated with the discovery of extensive systemic lymphadenopathy (Table).

The CNS infiltration of malignant lymphocyttoplasmic cells is recognized as the Bing-Neel syndrome (BNS), a constellation of neurologic manifestations secondary to Waldenstrom macroglobulinemia (WM). Although BNS is typically identified in those with established WM, in 15%–36% of cases, it represents the initial clinical presentation of the disorder.13 The early recognition of the BNS carries considerable implications, given that the administration of the Bruton tyrosine kinase, ibrutinib, has been demonstrated to produce response rates of greater than 90%.14 A particular case of the BNS that involved enhancement of the optic nerves and the left optic sheath exhibited a rapid, dramatic, and durable response to ibrutinib lasting more than 36 months.15

A paraneoplastic syndrome resulting from her hematologic malignancy could explain her episodes of ON preceding the diagnosis of smoldering lymphoma. Although, this is unlikely due to the rare occurrence of paraneoplastic disorders with hematologic malignancies, and our patient’s protracted time course of visual stability.10 Moreover, the underlying malignancy in paraneoplastic disorders is typically identified within the first few years after neurologic symptom onset.

ON, because of paraneoplastic etiologies such as with the collapsin response mediator protein 5, may present with optic disc edema and may coexist with retinitis and uveitis.17 Although the optic nerve may show high signal abnormality, the nerve rarely
enhances in this condition, and the optic neuropathy is progressive in nature, which was different than our patient.

**Histologic Diagnosis**

Serum protein electrophoresis showed hypogammaglobulinemia and a spike in the alpha-2 region. CSF flow cytometry demonstrated 50% phenotypically abnormal Ig kappa light chain–positive and CD5+CD19 B cells. Immunofixation results showed a low concentration of IgG kappa monoclonal gammapathy with suppression of normal IgG levels. Biopsy of the left supraclavicular lymph node confirmed a B-cell lymphoma, likely chronic lymphocytic lymphoma (CLL) vs small lymphocytic lymphoma.

**Final Diagnostic Considerations and Treatment Plan**

Recurrent bilateral ON and perineuritis in our patient were thought to be secondary to seronegative NMOSD, and her chronic immunosuppression most likely unmasked the hematologic malignancy. Although lymphoma can cause recurrent, asynchronous bilateral ON, it was felt that the spinal cord leptomeningeal infiltration observed later in her disease course was secondary to CNS infiltration of her systemic lymphoma. With the lymphoma diagnosis confirmed, treatment with the Bruton tyrosine kinase (BTK) inhibitor acalabrutinib was initiated, and rituximab was continued. Rituximab is often part of the armamentarium for the treatment of CLL in younger individuals, whereas BTK inhibitors are superior to standard chemotherapy for treatment of CLL in older adults.

Combination therapy with the addition of the anti-CD20 monoclonal antibody rituximab to a BTK inhibitor for the treatment of CLL has been evaluated in several studies, without superior outcomes compared with monotherapy with a BTK inhibitor. However, such may be related to the ability of BTK inhibitors to downregulate the cell surface expression of CD20, with the potential consequence of rendering subsequent anti-CD20 therapy of little to no utility. With this principle in mind, combination therapy in our patient with recurrent ON and lymphoma might be an effective and reasonably safe strategy, albeit while specifically using a stepwise sequence, administering anti-CD20 therapy first, followed by the application of the BTK inhibitor.

**Discussion**

CNS invasion by systemic hematologic malignancies has been well described and can involve the brain, the spine, or the leptomeninges and can present with cranial nerve palsies, headache, radiculopathy, or spinal cord signs. Non-Hodgkin lymphoma and systemic low-grade lymphomas invade the CNS in approximately 8% and 3% of cases, respectively. This can be contrasted with the common involvement of leptomeninges and brain parenchyma observed in up to 70% of cases of primary CNS lymphoma. The latter also presents with ocular involvement in about 25% of newly diagnosed cases.

The rate of CNS invasion by other systemic malignancies such as CLL appears to be less common and remains understudied. A series of 7 patients with indolent B-cell lymphoma and CNS involvement demonstrated the following common characteristics: bone marrow involvement at the time of lymphoma diagnosis (6/7 patients) and systemic or CNS high-grade histologic transformation (4/7 patients), which were not present in our patient.

Autopsy studies suggest that malignant cell infiltration of the optic nerve occurs in only approximately 18% of acute and 16% of chronic systemic leukemia cases. However, the extrapolation of an incident rate of such an important disease process from autopsy investigations represents a potentially serious confounding error of ascertainment bias. Alternately, our broader search leads us to conclude that the potential for both neoplastic infiltration and the predilection to cause leptomeningeal carcinomatosis/lymphoma of the anterior visual segments is considerably more common. Systematic ascertainment has demonstrated a rate as high as 90%, with a concordance rate of systemic involvement in greater than half of those with histopathologic confirmation of lymphomatous infiltration of the optic nerve.

A study involving patients with confirmed leptomeningeal carcinomatosis revealed that vision loss was the predominant ocular symptom in over 70%, while half reported that their visual disturbance was their initial and the corresponding symptom which prompted them to seek out medical attention. Along with mimicking the symptoms and semiology of ON and perineuritis, optic nerve malignant infiltration and leptomeningeal carcinomatosis can initially exhibit corticosteroid treatment response characteristics reminiscent of a broad spectrum of neuroimmunologic and neuroinflammatory disorders of the optic nerve and optic nerve sheath.

The potential for the erroneous underestimation of the true incidence rates for the involvement of the anterior visual system in cancer should mandate that the methodology for future staging investigations includes both a prospective and systematic search for the pathobiology of visual system syndromes that occur in these patients (Table). To this point, a potential diagnostic confounder in the case of our patient was that optic nerve biopsy was not performed, principally due to the invasive nature of the procedure. However, it is crucial for us to underscore here, that given the complexity surrounding the diagnosis of malignant infiltration and leptomeningeal carcinomatosis localized to the anterior visual system, when less invasive diagnostic methods fail to elucidate the pathobiology of such processes, then directed biopsy must be considered imperative, and even of justifiable urgency.

**Acknowledgment**

The authors thank the National Multiple Sclerosis Society and Mr. Jason Ooi and Dr. Matthew Parsons for their development of Figure 1 which details the complex chronological semiology of this case.
Study Funding

This work was funded by the National Multiple Sclerosis Society. The authors thank Mr. Jason Ooi and Dr. Matthew Parsons for the development of Figure 1, which was funded by the Frohman Foundation: Innovating Precision Care Through Discovery in Molecular Medicine.

Disclosure

D.A. Pimentel Maldonado has no disclosures. R. Lisak, over the past 2 years, has been funded for research support by the NIH, National Multiple Sclerosis Society (USA), Mallinckrodt Pharmaceuticals, Genentech, Teva Pharmaceuticals, Novartis, MedImmune, and Chugai. He has served as a consultant to GLG, Syntimmune, Alexion, AlphaSites, Insights Consulting, Informa Pharma Consulting, and Slingshot Consulting. He has served on the speaker’s bureau for Teva Pharmaceuticals (nonbranded talks only). S.L. Galetta has received consultant fees from Genentech. L.J. Balcer is editor-in-chief of the Journal of Neuro-Ophthalmology. T. Varkey has no disclosures. A. Goodman has served as a consultant and received honoraria from Janssen and Novartis. He has received research support from the following: Biogen, Genzyme Sanofi, and Atara. J. Graves unrelated to the current work, over the past year has grant/contract research support from the National MS Society, Biogen, and Octave Biosciences. She serves on a steering committee for a trial supported by Novartis. She has received honoraria for a nonpromotional, educational activity for Sanofi-Genzyme. She has received speaker fees from Alexion and BMS and served on an advisory board for Genentech. S.D. Newsome has received consultant fees for scientific advisory boards from Biogen, Genentech, Celgene, EMD Serono, Novartis, and Greenwich Biosciences; is an advisor for Autobahn Therapeutics and BioIncept; is a clinical adjudication committee member for a MedDay Pharmaceuticals clinical trial; and has received research funding (paid directly to institution) from Biogen, Novartis, Genentech, National MS Society, Department of Defense, and Patient-Centered Outcomes Institute. M.K. Racke is an employee of and owns stock in Quest Diagnostics Critical revision of the manuscript for intellectual content. Andrew Goodman, MD, PhD; Jennifer Graves, MD, PhD; and Scott Zamvil, MD, PhD have received research funding (paid directly to institution) from Biogen, Genentech, Celgene, EMD Serono, Novartis, Roche/Genentech, and Teva Pharmaceuticals, Inc., and has served or serves on Data Safety Monitoring Boards for Lilly, BioMS, Teva, and Opera Therapeutics. Currently, S.S. Zamvil receives grant research support from the NIH, the NMSS, The Maisin Foundation, Biogen, and Celgene. E.M. Frohman has received speaker honoraria from Genzyme, Novartis, Janssen, and Alexion. T.C. Frohman has received speaker fees from Alexion. Go to Neurology.org/NN for full disclosure.

Publication History

Received by Neurology: Neuroimmunology & Neuroinflammation May 12, 2022. Accepted in final form September 12, 2022.

Appendix Authors

| Name                  | Location                                      | Contribution                                           |
|-----------------------|-----------------------------------------------|-------------------------------------------------------|
| Daniela A. Pimentel Maldonado, MD, MSCR | Department of Neurology Johns Hopkins Hospital | Conception, manuscript drafting, clinical and imaging review, and critical revision of the manuscript |
| Robert Lisak, MD       | Department of Neurology Wayne State University | Critical revision of the manuscript for intellectual content |
| Steven Galetta, MD     | Department of Neurology New York University   | Critical revision of the manuscript for intellectual content |
| Laura Balcer, MD, MSCE | Department of Neurology New York University   | Critical revision of the manuscript for intellectual content |
| Thomas Varkey          | Dell Medical School at University of Texas at Austin | Critical revision of the manuscript for intellectual content |
| Andrew Goodman, MD     | Department of Neurology University of Rochester | Critical revision of the manuscript for intellectual content |
| Jennifer Graves, MD, PhD | Department of Neurosciences University of California at San Diego | Critical revision of the manuscript for intellectual content |
| Michael K. Racke, MD   | Quest Diagnostics                              | Critical revision of the manuscript for intellectual content |
| Scott S. Zamvil, MD, PhD | Department of Neurology Program in Immunology, University of California at San Francisco | Conception and critical revision of the manuscript for intellectual content |
| Scott Newsome, DO      | Department of Neurology Johns Hopkins Hospital | Conception and critical revision of the manuscript for intellectual content |
| Elliot M. Frohman, MD, PhD | Distinguished senior Fellow (Sabbatical) Laboratory of Neuroimmunology of Professor Lawrence Steinman, Stanford University School of Medicine | Conception and critical revision of the manuscript for intellectual content |
| Teresa C. Frohman, MPAS, PA-C | Distinguished senior Fellow (Sabbatical) Laboratory of Neuroimmunology of Professor Lawrence Steinman, Stanford University School of Medicine | Conception and critical revision of the manuscript for intellectual content |

References

1. Anadani N, Hyland M, Cruz RA, et al. Treating MS after surviving PML: discrete strategies for rescue, remission, and recovery patient 1: from the national multiple sclerosis society case conference proceedings. Neurol Neuroimmunol Neuroinflamm. 2021;8(1):e929. doi: 10.1212/NXI.0000000000000929.
2. Greenberg BM, Graves D, Remington G, et al. Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success. Mult Scler. 2012;18(7):1022-1026.
3. Nakajima H, Hosokawa T, Sugino M, et al. Visual field defects of optic neuritis in neuromyelitis optica compared with multiple sclerosis. BMC Neurol. 2010;10:45.
4. Bennett JL. Optic neuritis. Continuum (Minneap Minn). 2019;25(5):1236-1264.
5. Ramanathan S, Prelog K, Barnes EH, et al. Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. Mult Scler. 2016;22:470-482.
